Reduced lung-cancer mortality with volume CT screening in a randomized trial

New England Journal of Medicine

Volumn 382, Issue 6, 2020, Pages 503-513

  De Koning, H J ^a   Van Der Aalst, C M ^a   De Jong, P A ^c   Scholten, E T ^d   Nackaerts, K ^l   Heuvelmans, M A ^f   Lammers, J W J ^c   Weenink, C ^d   Yousaf Khan, U ^a   Horeweg, N ^e   Van'T Westeinde, S ^b   Prokop, M ^j   Mali, W P ^c   Mohamed Hoesein, F A A ^c   Van Ooijen, P M A ^g   Aerts, J G J V ^a   Den Bakker, M A ^b   Thunnissen, E ^k   Verschakelen, J ^l   Vliegenthart, R ^h   Walter, J E ^f,i   Ten Haaf, K ^a   Groen, H J M ^h   Oudkerk, M ^f,i   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Department of Orthopaedic Surgery   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Faculty of Medical Sciences   (Netherlands)

^g Data Science Center in Health   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ PHS Groningen   (Netherlands)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BELGIUM; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NETHERLANDS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; FALSE POSITIVE RESULT; HEALTH SERVICE; INCIDENCE; LUNG TUMOR; MORTALITY; MULTICENTER STUDY; PROCEDURES; REGISTER; SEX FACTOR; SMOKING;

AGED; BELGIUM; CONE-BEAM COMPUTED TOMOGRAPHY; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MEDICAL OVERUSE; MIDDLE AGED; NETHERLANDS; REGISTRIES; SEX FACTORS; SMOKING;

EID: 85078946747     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1911793     Document Type: Article

References (38)

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68: 394-424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68: 7-30.
3. Tobacco: data and statistics. Geneva: World Health Organization, 2019 (http:// www .euro .who .int/ en/ health -topics/ disease -prevention/ tobacco/ data -and -statistics).
4. Leon ME, Peruga A, McNeill A, et al. European Code against Cancer, 4th edition: tobacco and cancer. Cancer Epidemiol 2015;39: Suppl 1: S20-S33.
5. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365: 395-409.
6. The National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial. J Thorac Oncol 2019;14: 1732-42.
7. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014;160: 311-20.
8. Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive Services Task Force recommendation. Ann Intern Med 2013;159: 411-20.
9. van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med 2016;4: 749-61.
10. Health Council, WBO Committee. Population Screening Act: CT screening on lung cancer. The Hague: Health Council of the Netherlands, 2000.
11. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007;120: 868-74.
12. van Klaveren RJ, de Koning HJ, Mulshine J, Hirsch FR. Lung cancer screening by spiral CT: what is the optimal target population for screening trials? Lung Cancer 2002;38: 243-52.
13. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361: 2221-9.
14. Yousaf-Khan U, Horeweg N, van der Aalst C, Ten Haaf K, Oudkerk M, de Koning H. Baseline characteristics and mortality outcomes of control group participants and eligible non-responders in the NELSON lung cancer screening study. J Thorac Oncol 2015;10: 747-53.
15. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J 2013;42: 1659-67.
16. Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax 2017;72: 48-56.
17. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer 2006;54: 177-84.
18. Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncol 2016;17: 907-16.
19. Walter JE, Heuvelmans MA, de Bock GH, et al. Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: the NELSON study. Lung Cancer 2018;125: 103-8.
20. Xie X, Willemink MJ, Zhao Y, et al. Inter- and intrascanner variability of pulmonary nodule volumetry on low-dose 64-row CT: an anthropomorphic phantom study. Br J Radiol 2013;86: 20130160.
21. Xie X, Zhao Y, Snijder RA, et al. Sensitivity and accuracy of volumetry of pulmonary nodules on low-dose 16- and 64-row multi-detector CT: an anthropomorphic phantom study. Eur Radiol 2013;23: 139-47.
22. Horeweg N, van Klaveren RJ, Groen HJ, et al. Blinded and uniform cause of death verification in a lung cancer CT screening trial. Lung Cancer 2012;77: 522-5.
23. Yousaf-Khan AU, van der Aalst CM, Aerts JGJV, den Bakker MA, de Koning HJ. Uniform and blinded cause of death verification of the NELSON lung cancer screening participants. Lung Cancer 2017;111: 131-4.
24. Walter JE, Heuvelmans MA, Ten Haaf K, et al. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study. Thorax 2019;74: 247-53.
25. Fritz APC, Jack A, Shanmugaratnam K, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization, 2000.
26. Yousaf-Khan AU, van der Aalst CM, de Jong PA, et al. Cancer stage shift and treatment shift in the NELSON lung cancer screening trial: implications for clinicians. Rotterdam, the Netherlands: Erasmus University, 2018.
27. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 2013;119: 3976-83.
28. Becker N, Motsch E, Trotter A, et al. Lung cancer mortality reduction by LDCT screening - results from the randomized German LUSI trial. Int J Cancer 2019 June 4 (Epub ahead of print).
29. Ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev 2015;24: 154-61.
30. van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax 2010;65: 600-5.
31. Heijnsdijk EAM, Csanadi M, Gini A, et al. All-cause mortality versus cancerspecific mortality as outcome in cancer screening trials: a review and modeling study. Cancer Med 2019;8: 6127-38.
32. Patz EF Jr, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014;174: 269-74.
33. Ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Community Health 2015;69: 1035-9.
34. Patz EF Jr, Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol 2016;17: 590-9.
35. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol 2017;18(12): e754-e766.
36. Ten Haaf K, Jeon J, Tammemagi MC, et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med 2017;14(4): e1002277.
37. Ten Haaf K, Tammemagi MC, Bondy SJ, et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a populationbased setting: a microsimulation modeling analysis in Ontario, Canada. PLoS Med 2017;14(2): e1002225.
38. Field JK, de Koning H, Oudkerk M, et al. Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion. ESMO Open 2019;4(5): e000577.